|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.07.26 - 04:48
|
Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend? (RTTNews)
|
|
|
Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue outlook on strong commercial momentum; and MapLight Therapeutics, which staged a sharp rebound after a recent selloff, among others....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.07.26 - 18:33
|
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026 (GlobeNewswire EN)
|
|
|
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance....
|
|
|
15.06.26 - 14:03
|
Preclinical Data for OPKO Biologics′ OPK8801001 in Acromegaly Presented at ENDO 2026 (GlobeNewswire EN)
|
|
|
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available here, was presented by Moran Golan, Ph.D., Director of Preclinical & Clinical Pharmacology at OPKO Biologics....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
